Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report)’s stock price traded up 4.5% during mid-day trading on Thursday . The company traded as high as $33.95 and last traded at $33.83. 28,027 shares were traded during mid-day trading, a decline of 95% from the average session volume of 514,919 shares. The stock had previously closed at $32.37.
Analyst Upgrades and Downgrades
SYRE has been the topic of a number of analyst reports. Wedbush assumed coverage on shares of Spyre Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. Evercore ISI began coverage on shares of Spyre Therapeutics in a research note on Tuesday, July 16th. They issued an “outperform” rating for the company. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $43.43.
View Our Latest Stock Report on SYRE
Spyre Therapeutics Stock Performance
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.04. As a group, equities analysts anticipate that Spyre Therapeutics, Inc. will post -3.68 earnings per share for the current year.
Institutional Investors Weigh In On Spyre Therapeutics
Several institutional investors have recently modified their holdings of SYRE. Amalgamated Bank acquired a new position in Spyre Therapeutics during the second quarter worth $28,000. Quest Partners LLC purchased a new stake in shares of Spyre Therapeutics in the 2nd quarter worth about $36,000. SG Americas Securities LLC acquired a new stake in Spyre Therapeutics in the 2nd quarter valued at about $130,000. Carlyle Group Inc. purchased a new position in Spyre Therapeutics during the 2nd quarter valued at about $227,000. Finally, Profund Advisors LLC acquired a new position in Spyre Therapeutics during the second quarter worth about $296,000. Hedge funds and other institutional investors own 80.39% of the company’s stock.
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
See Also
- Five stocks we like better than Spyre Therapeutics
- What Are Trending Stocks? Trending Stocks Explained
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Investing in Travel Stocks Benefits
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Dividend Capture Strategy: What You Need to Know
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.